Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy Of S-1226 In Hospitalized Subjects With Moderate Severity Covid-19 Bronchiolitis/Pneumonia

Next Previous
Trial Profile

A Randomized, Open-Label, Controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy Of S-1226 In Hospitalized Subjects With Moderate Severity Covid-19 Bronchiolitis/Pneumonia

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbon dioxide/perflubron (Primary)
  • Indications Bronchiolitis; COVID-19 pneumonia
  • Focus Adverse reactions; Proof of concept
  • Sponsors SolAeroMed

Most Recent Events

  • 16 Aug 2021 Status changed from not yet recruiting to suspended as per Sponsor decision.
  • 11 Jun 2021 Planned primary completion date changed from 31 May 2021 to 31 Oct 2021.
  • 11 Jun 2021 Planned initiation date changed from 15 Feb 2021 to 15 Jun 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top